Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification.

Several PCa biomarkers have been developed either alone or in combination with clinical variables to improve csPCa detection. SelectMDX® score includes genomic markers, age, PSA, prostate volume, and digital rectal examination. Several studies showed consistence in the ability to improve detection of csPCa, avoidance of unnecessary prostate biopsies, helpful in decision making for clinical benefit of PCa patients with future well designed, and impactful studies.